Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.45 |
| ▸ | AGXT | P21549 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18579815 | 1.00 | IDO1 (0.46) | IDO1CHRNB2CHRNA4TAAR1AGXT | |
| SCHEMBL18580195 | 1.00 | IDO1 (0.46) | IDO1CHRNB2CHRNA4TAAR1AGXT | |
| SCHEMBL23647056 | 0.84 | IDO1 (0.43) | IDO1CHRNB2CHRNA4TAAR1AGXT | |
| SCHEMBL2554445 | 0.83 | TAAR1 (0.52) | IDO1TAAR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL20995917 | 0.83 | TSHR (0.48) | IDO1TAAR1AGXTSLC1A3SLC1A2 | |
| SCHEMBL17227561 | 0.82 | LOXL2 (0.43) | IDO1CHRNB2CHRNA4TSHRMAOA | |
| SCHEMBL14310474 | 0.81 | TSHR (0.46) | IDO1TAAR1AGXTSLC1A3SLC1A2 | |
| SCHEMBL12549624 | 0.81 | TSHR (0.46) | IDO1TAAR1AGXTSLC1A3SLC1A2 | |
| SCHEMBL92279 | 0.81 | TSHR (0.46) | IDO1TAAR1AGXTSLC1A3SLC1A2 | |
| SCHEMBL5728580 | 0.80 | IDO1 (0.50) | IDO1CHRNB2CHRNA4TAAR1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| US-12065445-B2 | CDK2 inhibitors and methods of using the same | CEDILLA THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4284365-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117177744-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230109076-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126719-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126720-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| EP-0912505-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6133319-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0912505-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997049680-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-31 | — | — | WO | disclosed |
| US-5171753-A | Derivatives of 2-amino-1-phenylethanol having antiulcer activity | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | IDO1 2290/4885CHRNB2 3330/4885CHRNA4 3770/4885 |
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | IDO1 3624/4885CHRNB2 4536/4885CHRNA4 4707/4885 |
| US-20230109076-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | IDO1 3624/4885CHRNB2 4536/4885CHRNA4 4707/4885 |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | IDO1 2587/4885CHRNB2 1010/4885CHRNA4 2016/4885 |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | IDO1 2290/4885CHRNB2 3330/4885CHRNA4 3770/4885 |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | IDO1 1842/4885CHRNB2 3049/4885CHRNA4 3845/4885 |
| US-12065445-B2 | CDK2 inhibitors and methods of using the same | CDK2, CDK20, CDK1 | IDO1 3620/4885CHRNB2 4712/4885CHRNA4 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.